Brightseed

Brightseed sits at the intersection of two powerful trends — AI-driven discovery and "food as medicine" — with a defensible platform rather than a single product. Its Forager AI system maps the bioactive compounds in plants, fungi, and microbes and predicts how they interact with human biological targets, screening millions of molecules in silico to surface functional-ingredient candidates far faster than wet-lab discovery. That is a data-and-compute moat that compounds: every validated compound enriches the database and makes the next prediction sharper. Critically, Brightseed doesn't only license the tool — it commercializes its own ingredients, including fiber-based bioactives targeting gut and metabolic health, giving it both platform economics and product upside. The commercial validation is real: it raised a $68M Series B led by Temasek in 2022 (roughly $120M total) and has signed partnerships with genuine ingredient and CPG heavyweights — ADM, Danone, and ofi — the kinds of partners who supply the world's food and would not engage a science-project. As GLP-1 drugs reshape how consumers think about metabolic and gut health, and as CPG brands hunt for scientifically characterized ingredients to replace vague "plant-based" claims, Brightseed offers exactly the validated, naturally derived compounds the market is beginning to demand. It is one of the cleanest bets that AI can turn "food as medicine" into shippable products.